Danaher Corporation $DHR Holdings Increased by Hanson & Doremus Investment Management

Hanson & Doremus Investment Management raised its position in shares of Danaher Corporation (NYSE:DHR) by 5,414.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,136 shares of the conglomerate’s stock after acquiring an additional 4,061 shares during the period. Hanson & Doremus Investment Management’s holdings in Danaher were worth $916,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Aspiriant LLC grew its position in shares of Danaher by 113.4% during the third quarter. Aspiriant LLC now owns 9,021 shares of the conglomerate’s stock worth $1,999,000 after buying an additional 4,794 shares in the last quarter. Holcombe Financial Inc. bought a new stake in shares of Danaher in the third quarter worth $1,139,000. Howard Capital Management LLC raised its holdings in Danaher by 197.9% in the third quarter. Howard Capital Management LLC now owns 12,641 shares of the conglomerate’s stock valued at $2,801,000 after acquiring an additional 8,397 shares in the last quarter. Goelzer Investment Management Inc. raised its holdings in Danaher by 4,817.7% in the third quarter. Goelzer Investment Management Inc. now owns 56,308 shares of the conglomerate’s stock valued at $12,475,000 after acquiring an additional 55,163 shares in the last quarter. Finally, Baugh & Associates LLC bought a new position in Danaher during the 3rd quarter valued at $16,100,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 1.1%

NYSE:DHR opened at $228.87 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a 50 day moving average of $214.04 and a 200-day moving average of $195.97. The firm has a market capitalization of $160.89 billion, a PE ratio of 40.65, a price-to-earnings-growth ratio of 2.91 and a beta of 0.76. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 EPS. Analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DHR shares. Morgan Stanley boosted their target price on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Guggenheim increased their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. UBS Group began coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. Royal Bank Of Canada lifted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Finally, TD Cowen boosted their price objective on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.